Decision Diagnostics Corp (OTCMKTS:DECN) has been surging since recent developments of retirement of debt, litigation legal victory, and expanding partnerships and business relationships. The stock has risen 90% since the beginning of the year and hit an intra-day high of $0.24 which is within $0.02 of its 52-week high.
DECN has a long base over 52 weeks long and finally break out on massive volume. This provided much needed liquidity to the stock and has been trying to make strides forward. After a few weeks of consolidations since its last price surge, DECN looks to be ready to surpass its previous highs. The share price traded as high as $1.00 in late 2013. If the stock should reach those levels again, it would gain over 440% from current levels.
Litigation campaigns from Johnson & Johnson LifeScan, prior to the regulatory approval and Genstrip product introduction, began where Johnson and Johnson’s made threats and intimidation to prevent the introduction of Genstrip to the diabetic population. J&J expanded its strategy through a communication campaign targeting all existing and prospective Genstrip customers. The company threatened to sue any commercial Genstrip purchaser for patent infringement. Because of this DECN eliminated its marketing plans for the Genstrip product through all second and third party seller.
DECN will likely receive significant damages from Johnson and Johnson given the recent ruling in favor of DECN and J&Js questionable use of patent intimidation to create a foothold on the market. A district judge ordered that J&J make a bond of $12.7M to be lodged. DECN will likely receive more damages for J&Js actions and behavior that had severe adverse financial impact to DECN.
DECN has spent the last several years planning and developing several new products that are finally ready to be released this year. The new products are for diagnostic testing and other devices. In addition, DECN will now be able to and is poised to sell millions of Genstrip to diabetic patients that are superior and significantly cheaper than what is currently available on the market. DECN has a contract manufacturer domestically and internationally to scale operations as needed.
We have a Monster Pick Coming. Subscribe Right Now!
DECN is currently trading at a $10.13 million market valuation. Given the recent developments of the legal victory and the fact it can now sell millions of Genstrips due to the resolution of the patent assertion by J&J sets DECN for significant future success. In addition to the fact the company has developed several new products ready for release should further ignite this exciting story. Stay tuned as we will update as more developments come available.
We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapspot so you know what’s going on with DECN.
Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.
Subscribe To Microcap Newsletter
By entering your email address you agree to get email updates from Microcap Spotlight. We'll respect your privacy and unsubscribe at any time.